ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2017
Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Pediatric-Onset Multiple Sclerosis in Tyrol, Austria: Epidemiology, Clinical Profile and Treatment Patterns from a Single Center (2015-2024).Children (Basel, Switzerland) · 2025Article
- Healthcare use before paediatric multiple sclerosis onset differs by age and sex: a nationwide cohort study.BMJ neurology open · 2025Article
- Rituximab treatment in pediatric-onset multiple sclerosis.European journal of neurology · 2024Article
- Multiple sclerosis in a 4-year-old boy: a case report and literature review.Frontiers in neurology · 2024Article
- Pediatric Multiple Sclerosis: Changing the Trajectory of Progression.Current neurology and neuroscience reports · 2023Review
- Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic.Multiple sclerosis and related disorders · 2021Article
- Teriflunomide: Pediatric First Approval.Paediatric drugs · 2021Review
- Aggressive multiple sclerosis (2): Treatment.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Multiple Sclerosis in Children: Current and Emerging Concepts.Seminars in neurology · 2020Review
- Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.Current treatment options in neurology · 2019Review
- Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies.Children (Basel, Switzerland) · 2019Review
- Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS).Pediatric health, medicine and therapeutics · 2019Review
- Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pediatric-onset multiple sclerosis (POMS) is rarer than adult-onset disease, and represents a different diagnostic and treatment challenge to clinicians. We review POMS clinical and radiographic presentations, and explore important differences between POMS and adult-onset MS natural histories and long-term outcomes. Despite having more active disease, current treatment guidelines for patients with POMS endorse the off-label use of lower-efficacy disease-modifying therapies (DMTs) as first line. We review the available MS DMTs, their evidence for use in POMS, and the contrasting treatment strategies of high-efficacy early treatment and escalation therapy. We introduce a new treatment approach, the "high-efficacy early treatment", or HEET strategy, based on using directly observed, high-efficacy intravenously infused DMTs as first-line therapies. Like other proposed POMS treatment strategies, HEET will need to be prospectively studied, and all treatment decisions should be determined by an experienced neurologist, the patient, and his/her parents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.